Much Awaited Cardiac Safety Data of Tirzepatide Released

Published On 2025-08-04 02:45 GMT   |   Update On 2025-08-04 09:57 GMT
Advertisement

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile comparable to dulaglutide (Trulicity) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Among over 13,000 participants, tirzepatide also showed additional benefits, including a 16% reduction in all-cause mortality, improved kidney function, better glycemic control, and greater weight loss over three years.

SURPASS-CVOT is the first head-to-head Phase 3 cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. It was conducted in 30 countries spread over more than 4 years.The trial evaluated Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, against Trulicity (dulaglutide), a GLP-1 receptor agonist previously shown to offer cardiovascular benefits in the REWIND study.

Advertisement

Mounjaro met the trial's primary endpoint by demonstrating non-inferiority to Trulicity in reducing major adverse cardiovascular events (MACE-3), including cardiovascular death, myocardial infarction, or stroke. Although not adjusted for multiplicity, Mounjaro also showed additional benefits, including improved A1C levels, greater weight loss, better renal function, and reduced all-cause mortality.

Cardiovascular disease remains the leading cause of death among people living with type 2 diabetes," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. "The SURPASS-CVOT results show that Mounjaro preserved the cardioprotective benefit of Trulicity, a GLP-1 receptor agonist, while providing additional benefits, including greater kidney protection and a reduced overall risk of death. These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease."

Complete findings from the SURPASS-CVOT trial will be presented at the European Association for the Study of Diabetes (EASD) annual meeting in September 2025 and subsequently published in a peer-reviewed journal.

Meanwhile, tirzepatide is also being evaluated in another large-scale cardiovascular outcomes trial, SURMOUNT-MMO. This study is assessing whether the drug can reduce the risk of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or heart failure events in individuals with overweight and either established cardiovascular disease or multiple age-related risk factors. Results from SURMOUNT-MMO are expected in 2027.

Tags:    
Article Source : Press release

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News